SCHEMBL4492686

SCHEMBL4492686

COc1cccc(CCNc2nc3cc(OC)ccc3cc2C(=O)O)c1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CSNK2A2 P19784 2/20 0.55
CSNK2A1 P68400 2/20 0.55
JAK3 P52333 1/20 0.47
CHRM2 P08172 1/20 0.46
CHRM1 P11229 1/20 0.46
CHRM3 P20309 1/20 0.46
AKR1C3 P42330 1/20 0.46
MTNR1A P48039 2/20 0.46
MTNR1B P49286 2/20 0.46
CTSL P07711 1/20 0.45
CTSS P25774 1/20 0.45
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
KDM4E B2RXH2 1/20 0.45
ALDH1A1 P00352 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
TACR3 P29371 1/20 0.45
APEX1 P27695 1/20 0.44
MAPT P10636 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4488036 0.93 TACR3 (0.51) CSNK2A2CSNK2A1MEN1KMT2AKDM4E
SCHEMBL4480962 0.92 CSNK2A2 (0.48) CSNK2A2CSNK2A1MEN1KMT2AKDM4E
SCHEMBL4492756 0.92 MEN1 (0.48) CSNK2A2CSNK2A1AKR1C3MEN1KMT2A
SCHEMBL4497855 0.90 PTGDR (0.51) CSNK2A2CSNK2A1MEN1KMT2AKDM4E
SCHEMBL4487805 0.89 NFKB1 (0.48) CSNK2A2CSNK2A1MEN1KMT2ATACR3
SCHEMBL4500058 0.89 SMN1; SMN2 (0.53) MEN1KMT2AALDH1A1APEX1MAPT
SCHEMBL4484055 0.88 CSNK2A2 (0.52) CSNK2A2CSNK2A1MEN1KMT2AKDM4E
SCHEMBL4493553 0.87 KMT2A (0.57) MEN1KMT2AKDM4EALDH1A1MAPT
SCHEMBL4478359 0.87 PTGDR (0.46) CSNK2A2CSNK2A1MEN1KMT2AKDM4E
SCHEMBL4486308 0.87 PGK1 (0.50) CSNK2A2CSNK2A1MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7482455-B2 Chemical compounds SMITHKLINE BEECHAM CORPORATION (US) 2009-01-27 US claimed
EP-1556379-A4 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2007-06-13 EP claimed
US-20060106058-A1 Chemical compounds BURGESS JOELLE L 2006-05-18 US claimed
EP-1556379-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2005-07-27 EP claimed
WO-2004034985-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2004-04-29 WO claimed
US-7482455-B2 Chemical compounds SMITHKLINE BEECHAM CORPORATION (US) 2009-01-27 US disclosed
EP-1556379-A4 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2007-06-13 EP disclosed
US-20060106058-A1 Chemical compounds BURGESS JOELLE L 2006-05-18 US disclosed
EP-1556379-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2005-07-27 EP disclosed
WO-2004034985-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2004-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106058-A1 Chemical compounds YARS1, DAPK3, NEK3 CSNK2A2 239/4885CSNK2A1 248/4885JAK3 379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.